Aurobindo Pharma's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA), margins and net profit was also ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...

Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...

European shares dipped to a more than one-week low as investors reacted to corporate reports and U.S. tariffs impacting sectors like automotives and beverages. Companies like Ferrari and Sanofi saw ...